Sign In
Buy SVRA
$5.25
+0 (+0%)
At Close: Jun 03, 2026
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
04:05pm, Wednesday, 06'th Mar 2024
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate
Savara Announces New Employment Inducement Grant
08:05am, Friday, 02'nd Feb 2024
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new emp
3 stocks to turn $100 into $1,000 in 2024
06:40am, Thursday, 01'st Feb 2024
The previous year was prosperous for many investors, resulting in significant gains in the stock market. The outlook for 2024 seems promising, especially in the technology sector.
Savara to Present at Two Upcoming Healthcare Conferences
08:05am, Wednesday, 31'st Jan 2024
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participa
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
08:05am, Thursday, 21'st Dec 2023
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new s
Savara Added to the NASDAQ Biotechnology Index
08:05am, Wednesday, 20'th Dec 2023
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ B
Savara Announces New Employment Inducement Grant
04:05pm, Friday, 15'th Dec 2023
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new emp
Savara to Present at the Piper Sandler 35th Annual Healthcare Conference
08:05am, Tuesday, 21'st Nov 2023
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate
Savara to Present at the Jefferies London Healthcare Conference
04:05pm, Wednesday, 08'th Nov 2023
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate
Savara Announces New Employment Inducement Grant
04:05pm, Friday, 06'th Oct 2023
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new
3 Penny Stocks to Provide 1,000% Returns Over the Next Decade
07:29pm, Wednesday, 27'th Sep 2023
While penny stocks promise substantial potential gains, the reality is that sub-$5 stocks are among the riskiest investments. Their low price often reflects underlying issues like weak business models
The 3 Best Penny Stocks to Buy Now: September 2023
09:12am, Tuesday, 12'th Sep 2023
A new month arrives and with it comes new investment opportunities. We will not always need such a large capital to make our investments, for these penny stocks present us with good opportunities that
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
04:05pm, Tuesday, 05'th Sep 2023
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at t
Savara Announces New Employment Inducement Grant
04:05pm, Friday, 04'th Aug 2023
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new
Savara: A Speculative Play
11:50am, Sunday, 16'th Jul 2023
Today, we circle back on a small development firm called Savara for the first time in over two years. Its primary drug candidate is being developed for a rare affliction that has no approved therapies
